Susvimo® (ranibizumab intravitreal injection via ocular implant)

Susvimo is not recommended for approval/coverage despite its FDA indication for neovascular (wet) AMD, and use is discouraged because of significant safety concerns including a boxed warning for endophthalmitis; non‑FDA indications are not supported. The only stated requirement is prior documented response to at least two intravitreal VEGF inhibitor injections per the FDA indication, and no additional documentation requirements are specified.

"Treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VE..."

Sign up to see full coverage criteria, indications, and limitations.